Steven Saltman, MD
Endocrinology, Diabetes & Metabolism · Fullerton, CANPI 1770579153
Payments from drug & device makers
Across 488 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- Amgen$934
- Boehringer Ingelheim$538
- Abbott$485
- AstraZeneca$445
- plus $4K from 33 others
What the payments were for
- Travel & lodging$70%
- Food & beverage$8,34299%
- Education$451%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 95 | $1,380 |
| Novo Nordisk | 74 | $1,085 |
| Amgen(2 entities) | 71 | $934 |
| Boehringer Ingelheim | 25 | $538 |
| Abbott | 25 | $485 |
| AstraZeneca(2 entities) | 24 | $445 |
| Dexcom, Inc. | 23 | $434 |
| Sanofi-aventis U.S. LLC | 17 | $361 |
| Corcept Therapeutics | 11 | $318 |
| Insulet Corporation | 11 | $274 |
| AbbVie | 13 | $269 |
| Novartis | 10 | $208 |
| Mannkind Corporation | 10 | $200 |
| Bayer | 10 | $176 |
| IBSA Pharma Inc. | 15 | $151 |
| Recordati_rare_diseases_inc. | 5 | $149 |
| Lifescan, Inc. | 5 | $101 |
| Xeris Pharmaceuticals, Inc. | 4 | $91 |
| Ascendis Pharma Endocrinology Inc | 4 | $91 |
| Kyowa Kirin, Inc. | 3 | $84 |
| Radius Health, Inc. | 4 | $84 |
| Tandem Diabetes Care, Inc. | 3 | $78 |
| Sequel Med Tech, LLC | 3 | $61 |
| Amarin Pharma, Inc. | 3 | $53 |
| Madrigal Pharmaceuticals | 2 | $46 |
| Medtronic | 3 | $46 |
| Johnson & Johnson | 3 | $39 |
| Neurocrine Biosciences, Inc. | 1 | $32 |
| GRT US Holding, Inc. | 1 | $29 |
| Cequr Corporation | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $24 |
| Valeritas, Inc. | 1 | $24 |
| Amphastar Pharmaceuticals, Inc. | 1 | $22 |
| Bigfoot Biomedical Inc | 1 | $21 |
| Antares Pharma, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Pfizer | 1 | $18 |
| BETA Bionics, Inc. | 1 | $17 |
How this compares
$8,454 in reported general payments places this provider in the 70th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 90 | $143,137 |
| TrulicityDulaglutide | 111 | $134,656 |
| JardianceEmpagliflozin | 101 | $120,586 |
| MounjaroTirzepatide | 88 | $102,102 |
| JanuviaSitagliptin Phosphate | 82 | $96,154 |
| EliquisApixaban | 55 | $82,074 |
| FarxigaDapagliflozin Propanediol | 47 | $57,441 |
| Repatha SyringeEvolocumab | 25 | $29,896 |
| RybelsusSemaglutide | 12 | $23,201 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $22,106 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $21,965 |
| Victoza 3-PakLiraglutide | 18 | $21,893 |
| SynthroidLevothyroxine Sodium | 221 | $19,865 |
| Praluent PenAlirocumab | 22 | $14,974 |
| Humalog Kwikpen U-100Insulin Lispro | 50 | $14,151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $1,380 | $247,069256 claims |
| Novo NordiskOzempic, Rybelsus | $1,085 | $166,338102 claims |
| Boehringer IngelheimJardiance | $538 | $120,586101 claims |
| PfizerEliquis, Paxlovid | $18 | $84,88073 claims |
| AstraZenecaFarxiga | $445 | $57,44147 claims |
| AbbVieSynthroid, Armour Thyroid | $269 | $22,075241 claims |
| Sanofi-aventis U.S. LLCLantus | $361 | $4,94026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Fullerton
- John GilbertFullerton$1.1M
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Stanley HsiaLos Angeles$19.8M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
- David AhnNewport Beach$5.8M
- Shlomo MelmedLos Angeles$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.